Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?
This clinical-stage biotech advancing cancer therapies reported a notable insider sale as its lead candidates progress in early trials.
Overview
Medical and biotech-focused hedge fund Orbimed Advisors reported a notable sale in Enliven Therapeutics Inc (NASDAQ:ELVN).
The clinical-stage biotech is advancing cancer therapies recently annolunced promising data on a leukemia drug it is developing. Orbimed owns more than 10% of the company but recently lightened its stake.
Details
The asset manager reported the sale of 281,408 shares of common stock for approximately $12.67 million, according to an SEC Form 4 filing.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.